Ethanolamine Oleate bulk supplier for pharma manufacturers

Ethanolamine Oleate 5% Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 5%

Reference Brands: Generic formulations marketed under different names

Ethanolamine Oleate is a Gastrointestinal Drugs product available as Injection in strengths 5%. It corresponds to the reference brand Generic formulations marketed under different names. Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Ethanolamine oleate is a sclerosing and antivaricose agent used primarily in endoscopic sclerotherapy for the management of esophageal varices. It is administered by direct injection into or around variceal veins, where it produces localized endothelial damage leading to inflammation, thrombosis, and eventual sclerosis or closure of the abnormal vein. This mechanism helps control active bleeding and reduces the risk of rebleeding in patients with esophageal varices that have recently hemorrhaged.

Ethanolamine oleate is specifically indicated for patients with a history of bleeding esophageal varices and is not recommended for use in patients whose varices have not bled. Clinical evidence has not demonstrated a preventive benefit in non-bleeding varices, and its use in such cases does not reduce the likelihood of future hemorrhage. Importantly, ethanolamine oleate does not address the underlying cause of esophageal varices, namely portal hypertension. As a result, recanalization of treated veins and the development of collateral circulation may occur over time. For this reason, repeated sclerotherapy sessions may be necessary to maintain therapeutic control and manage recurrent variceal bleeding in affected patients.

Ethanolamine Oleate — third party manufacturing & bulk supply

Ethanolamine Oleate 5% is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ethanolamine Oleate is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ethanolamine Oleate listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ethanolamine Oleate →

Back to Listing

Frequently Asked Questions

Ethanolamine oleate is used as a sclerosing agent in the treatment and control of bleeding esophageal varices during endoscopic sclerotherapy procedures.

Ethanolamine oleate is made from ethanolamine combined with oleic acid, forming a synthetic sclerosing compound suitable for injectable medical use.

Ethanolamine oleate is commonly marketed under the trade name Ethanolamine Oleate Injection, without a widely established proprietary brand.

Ethanolamine oleate injection is manufactured by multiple pharmaceutical companies worldwide, including suppliers in the USA, EU, India, and other regulated markets.

The generic name is ethanolamine oleate.

There is no dominant branded name; it is generally sold as Ethanolamine Oleate Injection USP or INN.

Ethanolamine oleate is manufactured in several countries, including the United States, European Union nations, India, and other regions with approved sterile injectable manufacturing facilities.